Advertisement

Topics

Companies Related to "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" [Most Relevant Company Matches] - Page: 3 RSS

13:15 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Immune Tumor Response Multi component Immune Based" Companies 51–75 of 8,100+

Relevant

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...


Cylex Incorporated

The company Focus on the development oftechnology for the assessment of cell-mediated immune function.The technology integrates magnetic separation of blood cells with bioluminescent detection for the measurement of immune system function.

CBT Pharmaceuticals, Inc.

CBT Pharmaceuticals is a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. The company is advancing a pipeline of four development-stage assets. CBT-101, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pa...


Innate Immune, Inc.

Innate Immune, Inc. is a privately held biotechnology company focused on the discovery and development of drugs that modulate the activity of natural killer T cells for the treatment of immune disorders. The Company has licensed an extensive intellectual property portfolio from Stanford University, Dana Farber Cancer Institute and National Institutes of He...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

OncoMab™ GmbH

OncoMab™ GmbH's business is the development of human antibodies for the treatment of cancer. The OncoMab™ way is unique because the antibodies are not developed in mice or by genetic engineering, but are isolated directly from cancer patients. The OncoMab™ antibodies are part of the innate natural immunity against malignant cells. This innate immune system functions as the first defence agai...

Iomai

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, en...

Trillium Therapeutics Inc

Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery and development of innovative therapies for the treatment of immune-mediated disorders. The company’s therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoi...

Rheos Medicines

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-...

Immtech International

Immtech International is a biopharmaceutical company focusing on the discovery and development of therapeutic products for the treatment of opportunistic diseases and cancer in patients with compromised immune responses. The Company has two separate platform technologies for developing drugs, one based on developing a new class of molecules as pharmaceuticals and a second for developing a series ...

Implicit Bioscience Ltd

Implicit Bioscience Ltd is a public unlisted Australian biopharmaceutical company based in Brisbane (Australia) and Seattle, WA that develops drugs which modulate the host immune response to disease. Its business model is to mitigate both product risk and capital risk, through the in-licensing and development of clinical stage programs that have known safety profiles in man, and present opportunit...

Vaxon Biotech.

Vaxon Biotech, founded in early 2004 and based in Evry Genopole - France, is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of malignancies, including prostate, lung, breast and colon cancer. The company is based on an original discovery made by Dr. Kostas Kosmatopoulos and his team: optimized cryptic peptides. Vaxon Bi...

Telephus Medical LLC

Telephus Medical, located in San Diego, California, is developing a suite of monoclonal antibody products designed to neutralize key staphylococcal enzymes used to attach to host tissues, replicate and evade immune attack. These enzymes, are central components of the bacterial machinery staphylococci utilize to invade host tissues, evade the immune respons...

Vivaldi Biosciences Inc.

Vivaldi Biosciences is developing live attenuated influenza vaccines (LAIVs) with the potential for increased effectiveness in the prevention of emerging pandemic influenza and seasonal influenza. Vivaldi’s LAIVs are designed using proprietary reverse genetics and plasmid rescue technologies to truncate the influenza NS1 gene. The unique method of att...

Peptor

Peptor's mission is to become a leading developer of drugs for the specific treatment of autoimmune diseases. The company has targeted Diabetes, Rheumatoid Arthritis and other autoimmune diseases that lack curative treatment.Peptor's competitive edge is based on a proprietary technology platform which enables the manipulation of a key player in the immune system - Heat Shock Protein 60 (hsp60). Th...

Innate Therapeutics Limited

Innate Therapeutics Limited is a public unlisted biopharmaceutical company based in Auckland. The company is focused on the development of a new generation of immune response modifiers for potential use in the treatment of MS and other autoimmune diseases, a range of infectious diseases, certain cancers, and as a novel cellular and humoral adjuvant. For fu...

ImmunoBiology Limited (ImmBio)

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer. Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination. HspC...

Biothera Pharmaceutical Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a late clinical stage immunotherapeutic drug candidate that modulates key immune cells to recognize and kill cancer. Proof of concept has been established from single-arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymp...

TolerRx Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tolerance. These therapies are most appropriate for chronic conditions associated with adverse, misdirected, or undesirable immune responses. TolerRx's approach is unique and unprecedented, in that it wil...

Gliknik Inc.

Founded in 2007, Gliknik is a biopharmaceuticals company creating new therapies for patients with cancer and immune disorders. Gliknik expertise is in modulation of the immune system to fight disease. Gliknik was named a 2009 Maryland Incubator Company of the Year. Learn more at www.gliknik.com.

Parvus Therapeutics

Parvus Therapeutics Inc. is a privately held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune complexes that induce the in-vivo expansion of disease-specific T- and B-regulatory cells resulting in the restoration of immune homeostasis. Navacims can be readily be tailored to ...

Centocor, Inc.

The immune system has many secrets…but not for long. Centocor is fundamentally changing the treatment of immune-related disease. The immune system is the new frontier—and the way we view it is unique. Through the visionary science of biotechnology, we pioneer breakthrough biomedicines that transform patients’ lives

TILT Biotherapeutics Ltd

TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy (including checkpoint antibodies) with oncolytic viruses. The company’s patented technology is uniquely based on human observations on the effect of oncolytic adenoviruses on the adaptive immune system. www.tiltbio.com

Coridon Pty Ltd

Coridon is a privately held company headquartered in Brisbane Australia. The company was founded in 2000 for the purpose of developing DNA therapies for the prevention and treatment of viral infections such as Herpesvirus and Hepatitis C and therapeutic vaccines for the treatment of cancer.Our mission is to develop new DNA immunotherapies that achieve effective immune responses. These effective im...

Surface Oncology

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles...


More From BioPortfolio on "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks